Comparative Safety of Long-Acting vs. Short-Acting Erythropoiesis-Stimulating Agents Among Patients Undergoing Hemodialysis
Clin Pharmacol Ther. 2024 Apr 17. doi: 10.1002/cpt.3271. Online ahead of print.ABSTRACTBoth short-acting (epoetin alfa or beta) and long-acting (darbepoetin alfa or PEG-epoetin) erythropoiesis-stimulating agents (ESAs) are commonly prescribed for patients with kidney failure undergoing maintenance hemodialysis. We compared the risks of major adverse cardiovascular events (MACE) and of all-cause mortality associated with receipt of short- vs. long-acting ESAs. This retrospective cohort analysis included Medicare hemodialysis beneficiaries aged ≥ 18 years in the United States Renal Data System from January 2015 to December...
Source: Clinical Pharmacology and Therapeutics - April 17, 2024 Category: Drugs & Pharmacology Authors: Raj Desai Ikenna Unigwe Munaza Riaz Steven M Smith Ashutosh M Shukla Rajesh Mohandas Nakyung Jeon Haesuk Park Source Type: research
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials
ConclusionThese patient-reported satisfaction outcomes support the use of molidustat as a patient-centered treatment option for CKD-related anemia.Registration of clinical trialsClinicalTrials.gov Identifier: NCT03350321 (November 22, 2017).ClinicalTrials.gov Identifier: NCT03350347 (November 22, 2017). (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - July 26, 2023 Category: Urology & Nephrology Source Type: research
Weight-based vs fixed dosing of darbepoetin alfa for anemia following kidney transplantation
CONCLUSION: Weight-based and fixed dosing approaches for darbepoetin alfa were not different in the achievement of a hemoglobin concentration of at least 10 g/dL without blood transfusion at 12 weeks after darbepoetin alfa initiation, with significantly lower cumulative darbepoetin alfa utilization in the weight-based group. Weight-based dosing of darbepoetin alfa in PTA appears to be safe and effective, with the potential for significant patient and health-system cost savings.PMID:37471466 | DOI:10.1093/ajhp/zxad163 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - July 20, 2023 Category: Drugs & Pharmacology Authors: Jonathan Solis Nicole Wilson Teena Sam Tsung-Wei Ma Angelito Yango Bernard Fischbach Ann D Kataria Source Type: research
Weight-based vs fixed dosing of darbepoetin alfa for anemia following kidney transplantation
CONCLUSION: Weight-based and fixed dosing approaches for darbepoetin alfa were not different in the achievement of a hemoglobin concentration of at least 10 g/dL without blood transfusion at 12 weeks after darbepoetin alfa initiation, with significantly lower cumulative darbepoetin alfa utilization in the weight-based group. Weight-based dosing of darbepoetin alfa in PTA appears to be safe and effective, with the potential for significant patient and health-system cost savings.PMID:37471466 | DOI:10.1093/ajhp/zxad163 (Source: American Journal of Health-System Pharmacy : AJHP)
Source: American Journal of Health-System Pharmacy : AJHP - July 20, 2023 Category: Drugs & Pharmacology Authors: Jonathan Solis Nicole Wilson Teena Sam Tsung-Wei Ma Angelito Yango Bernard Fischbach Ann D Kataria Source Type: research
Desidustat in anaemia in patients with chronic kidney disease: a profile of its use
AbstractDesidustat (Oxemia™), a hypoxia-inducible factor prolyl hydroxylase inhibitor, is a promising new oral alternative to injectable erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia in patients with chronic kidney disease (CKD). Desidustat is approved in India for adults with CKD who are either not on dialysis or on dialysis. It is administered orally three times a week and dosage should be individualised based on the haemoglobin response of the patient. In clinical trials in patients with non-dialysis-dependent and dialysis-dependent CKD, desidustat was non-inferior to darbepoetin alfa and epoet...
Source: Drugs and Therapy Perspectives - July 13, 2023 Category: Drugs & Pharmacology Source Type: research
Comparative effectiveness and acceptability of HIF prolyl-hydroxylase inhibitors versus for anemia patients with chronic kidney disease undergoing dialysis: a systematic review and network meta-analysis
Conclusion: HIF-PHIs and ESAs have their characteristics and advantages in treating anemia undergoing dialysis. With the selected dose-adjusted mode, some HIF-PHIs appeared to be a potential treatment for DD-CKD patients when ompared with rhEPO, due to its effectiveness in decreasing the risk of RBC transfusion rate or regulating iron or lipid metabolism while achieving target Hb levels.Systematic Review Registration:https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=306511; Identifier: CRD42022306511 (Source: Frontiers in Pharmacology)
Source: Frontiers in Pharmacology - July 13, 2023 Category: Drugs & Pharmacology Source Type: research
Higher hemoglobin levels using darbepoetin alfa and kidney outcomes in advanced chronic kidney disease without diabetes: a prespecified secondary analysis of the PREDICT trial
ConclusionsIn the per-protocol set, the high-hemoglobin group demonstrated better kidney outcomes than the low-hemoglobin group, suggesting a potential benefit of maintaining higher hemoglobin levels in patients with advanced CKD without diabetes.Clinical trial registrationClinicaltrials.gov (identifier: NCT01581073). (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - June 8, 2023 Category: Urology & Nephrology Source Type: research
Comparison of Different Adjuvant Therapies for Hypothermia in Neonates with Hypoxic-Ischemic Encephalopathy: A Systematic Review and Network Meta-Analysis
ConclusionsCurrently, no combination therapy can reduce mortality, seizures, or abnormal brain imaging findings in neonatal hypoxic-ischemic encephalopathy. According to low quality evidence, HT combined with MT may reduce NDI. (Source: Indian Journal of Pediatrics)
Source: Indian Journal of Pediatrics - May 18, 2023 Category: Pediatrics Source Type: research
Abatacept as salvage therapy for life-threatening refractory autoimmune hemolytic anemia: a case report
Hematology. 2023 Dec;28(1):2208010. doi: 10.1080/16078454.2023.2208010.ABSTRACTAutoimmune hemolytic anemia (AIHA) can be life-threatening, if hemoglobin (Hb) levels continue to decline after established treatments with glucocorticoids, rituximab, intravenous immunoglobulins, and plasmapheresis. Impaired regulatory T cells (Treg) are proposed to alleviate AIHA development through decreased binding of CTLA-4 to antigen-presenting cells. Abatacept is a fusion protein with a CTLA-4 domain and is approved for use in rheumatoid arthritis. It mimics the immunosuppressive CTLA-4 effect of Treg. Thus, application of abatacept in re...
Source: Hematology - May 3, 2023 Category: Hematology Authors: Joerg Hoffmann Georg Schliesser Andreas Neubauer Source Type: research
Treatment satisfaction with molidustat in CKD-related anemia in non-dialysis patients: a post-hoc analysis of two clinical trials
ConclusionThese patient-reported satisfaction outcomes support the use of molidustat as a patient-centered treatment option for CKD-related anemia.Registration of clinical trialsClinicalTrials.gov Identifier: NCT03350321 (November 22, 2017).ClinicalTrials.gov Identifier: NCT03350347 (November 22, 2017). (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - April 24, 2023 Category: Urology & Nephrology Source Type: research
Real-Life Anemia Management Among Patients with Non-Dialysis-Dependent Chronic Kidney Disease in Three European Countries
CONCLUSION: Among ESA-treated patients, ESA initiation was in accordance with KDIGO guidelines, but subsequent monitoring of Hb and iron deficiency were suboptimal.PMID:37077414 | PMC:PMC10108867 | DOI:10.2147/IJNRD.S401598 (Source: International Journal of Nephrology and Renovascular Disease)
Source: International Journal of Nephrology and Renovascular Disease - April 20, 2023 Category: Urology & Nephrology Authors: Danilo Fliser Maria Mata Lorenzo Katherine Houghton Claire Ainsworth Martin Blogg Elena Gonz ález de Antona Sánchez Jose Portoles Source Type: research
